Immune Design Corp.
IMDZ
IMDZ was delisted on the 1st of April, 2019.
58 hedge funds and large institutions have $87.6M invested in Immune Design Corp. in 2017 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 9 closing their positions.
238% more call options, than puts
Call options by funds: $1.3M | Put options by funds: $386K
21% more capital invested
Capital invested by funds: $72.3M → $87.6M (+$15.3M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 22
11% less funds holding
Funds holding: 65 → 58 (-7)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.16M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$1.17M |
| 3 |
A
Abingworth
London,
United Kingdom
|
+$896K |
| 4 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$457K |
| 5 |
Renaissance Technologies
New York
|
+$407K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$1.2M |
| 2 |
NC
Nexthera Capital
New York
|
-$1.09M |
| 3 |
SIM
Spark Investment Management
New York
|
-$586K |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$567K |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$555K |
IMDZ Hedge Fund Activity: Q1 2017 in Review
58 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Immune Design Corp. (IMDZ) for Q1 2017, worth a combined $87.6M — up 21% from $72.3M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of IMDZ and 8 opened new positions — a net loss of 1 holder — while 22 trimmed existing stakes and 20 added.
The largest buyer was BlackRock, adding an estimated $5.16M. The largest seller was Putnam Investments, exiting entirely with an estimated $1.2M sold.
- 58 institutional investors held Immune Design Corp. (IMDZ) as of Q1 2017, down from 65 in Q4 2016.
- Funds reported $87.6M of Immune Design Corp. stock for Q1 2017, up 21% quarter-over-quarter.
- 8 funds opened new Immune Design Corp. positions in Q1 2017 and 9 closed out, a net change of -1 holder.
- The largest Immune Design Corp. buyer in Q1 2017 was BlackRock, an estimated $5.16M added.
- The largest Immune Design Corp. seller in Q1 2017 was Putnam Investments, an estimated $1.2M sold.
Based on aggregated 13F filings for Q1 2017.